One Case of Lamotrigine-induced Severe Erythema Multiforme Drug Eruption

doi:10.19803/j.1672-8629.2020.11.19

Abstract

Abstract: Objective To explore ways to treat Stevens Johnson syndrome induced by lamotrigine. Methods The diagnosis and treatment of one case of Stevens Johnson syndrome induced by lamotrigine was analyzed. The mechanism by which lamotrigine induced Stevens Johnson syndrome was discussed in combination with literature. Results The patient was diagnosed with Stevens Johnson syndrome on the 55th day he took lamotrigine. The drug was stopped immediately. His condition gradually improved after the treatment with intravenous methylprednisolone sodium succinate. Skin rash was significantly improved, and itching disappeared on the 19th day of withdrawal. Conclusion The use of lamotrigine should be stopped immediately should Stevens Johnson syndrome occur. Glucocorticoid and other drugs should be given as symptomatic treatment.

Key words: lamotrigine, Stevens Johnson syndrome, adverse reactions

CLC Number:

R994.11

WANG Xiao, WU Lingdi, WANG Jun, WEI Wei, WANG Weibo, WANG Haiying. One Case of Lamotrigine-induced Severe Erythema Multiforme Drug Eruption[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 835-837.

References

[1] Norio YF, Kojiro H, Koji T, et al. Comorbidity of Stevens Johnson syndrome and neutropenia associated with lamotrigine: a case report [J]. Gen Hosp Psychiatry, 2014, 36(6) : 761.e9-761.e11.
[2] CFDA. decides to revise the package insert of Lamotrigine Hydro-chloride Oral Solution[J]. Journal of Adverse Drug Reactions(药物不良反应杂志), 2012, 14(3): 201.
[3] Stefani A, Spadoni F, Siniscalchi A, et al.Lamotrigine inhibits Ca²⁺currents in cortical neurons: functional implications[J].Eur J Pharmacol, 2006, 307(1): 113-116.
[4] Sarco DP, Bourgeois BF.The safety and tolerability of newer antiepileptic drugs in children and adolescents[J].CNS Drugs, 2010, 24(5): 399-430.
[5] Ng PP, Sun YJ, Tan HH, et al.Detection of herpes simplex virus genomic DNA in various subsets of erythema multiforme by polymerase chain reaction[J]. Dermatology, 2003, 207(4): 349-353.
[6] He X,Zhang Y,Xu J, et al.Literature analysis of 77 cases of adverse reactions of lamotrigine[J]. China Pharmacovigilance(药物不良反应杂志), 2016,13(5): 303-305.
[7] Li DK, Jin YY, Tang G, et al.Martindale's Drug Dictionary[S]. 35th ed. 2009, 383-385.
[8] Codrea P, Tigaran S, Sidenius P, et al.Lamotrigine-induced rash-worth a rechallenge[J]. Acta Neurol Scand, 2005, 111(3): 191-194.
[9] Cheng XM, Li L, Tian YJ.Progress in the study of HLA-B1502 allele and severe cutaneous adverse reactions caused by antiep-ileptic drugs in different ethnic groups[J]. China Pharmacovigilance(药物不良反应杂志). 2011, 8(4) : 237-239.
[10] Myers AP, Watson TA, Strock SB.Drug reaction with eosinophilia and systemic symptoms syndrome probably induced by lamotrigine ginseng drug interaction[J]. Pharmacotherapy, 2015, 35(3): e9-12.
[11] Ginory A, Charncy-Catchpole M.Drug reaction with eosinophilia and systemic symptoms(dress)in an adolescent treated with lamotrigine[J]. J Pediatr Pharmacol Ther, 2013, 18(3): 236-240.
[12] Hirata I, Kimizu T, Ikeda T, et al.A fatal case of lamotrigine associated drug-induced hypersensitivity syndrome with fulminant myocarditis[J]. No To Hatatsu, 2013, 45(3): 243-244.
[13] Shi YW, Min F L, Zhou D, et al.HLA-A*2402 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions[J]. Neurology, 2017, 88(23): 2183-2191.
[14] Teh LK, Selvaraj M, Bannur Z, et al.Coupling Genotyping and Computational Modeling in Prediction of Anti-epileptic Drugs that cause Stevens Johnson Syndrome and Toxic Epidermal Necrolysis for Carrier of HLA-B*1502[J]. J Pharm Pharm Sci, 2016, 19(1): 147-160.
[15] Deng Y, Li S, Zhang L, et al.Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: A meta-analysis[J]. Seizure, 2018, 60: 163-171.
[16] Burkhart KK, Abernethy D, Jackson D.Data mining faers to analyze molecular targets of drugs highly associated with Stevens-Johnson syndrome[J]. J Med Toxicol, 2015, 11(2): 265-273.